Small Molecule Drugs


Skimune® can predict first-in-man hypersensitivity or adverse immune reactions to small molecule therapeutics.

Benefits of the Skimune® assay​

Detection of clinically relevant celluar immune responses
Validated against commercially available therapeutic small monoclonal drugs​
Available in combination with complementary assays
Non-animal system​
For more information on Skimune® assays and how they can help your business R&D please contact us​.
Get in touch

Case Study:


In collaboration with Pfizer (1) we validated our Skimune® explant assays against a range of small molecule drugs and compared results to T-cell proliferation cytokine release. The skin explant assay offers a human in vitro model with a novel endpoint to predict the potential of a drug to cause drug hypersensitivity reactions (DHRs) which standard toxicology tests do not offer. The skin damage observed in response to drug exposure is reflective of immune activation and the production of cytokine and other cytotoxic molecules by the activated T-cells.

The study outcome demonstrates that the skin explant assay could be used as a valuable predictive pre-clinical tool either as an independent test or in conjunction with in vivo assays.
(1) Toxicol Appl Phamacol. 2019: 369, 39-48. doi: 10.1016/j.taap.2019.02.005 Ahmed SS, Whritenour J, Ahmed MM, BibbyL, Darby L, Wang XN, Watson J, Dickinson AM.

Other application areas currently include:

Chemical Compounds

Read more

Cosmetics Ingredients

Read more

Antibody Drug Conjugates

Read more

Small Molecule Drugs

Read more

Biologics

Read more

Cellular Therapies

Read more

Get in touch

How can we assist?